The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN11390660     1-(2-nitroimidazol-1-yl)-3- (1...

Synonyms: KST-1B8111, NSC-318502, AC1L2XUW, NSC318502, AR-1B1067, ...
This record was replaced with 50981.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NSC318502


High impact information on NSC318502


Chemical compound and disease context of NSC318502


Biological context of NSC318502

  • Pharmacokinetics of Ro 03-8799 in mice bearing melanosarcoma: comparison with tumors without melanin [13].
  • From bivariate analysis, cumulative AUC for Ro 03-8799 has the most significant correlation with the development of peripheral neuropathy [3].
  • WBH markedly reduced Ro 03-8799 LD50/7d from 779 to 259 micrograms g-1 (P less than 0.001) [10].
  • These observations added to the reports concerning toxicology in monkeys and rats and radiosensitizing efficiency in the laboratory, suggest that Ro 03-8799 may prove to be much more effective sensitizer than misonidazole in man [14].
  • Glucose and lipid metabolism in the brain, liver and in a transplanted tumour were found to be variously altered within 2 to 3 h of administering single doses of the radiosensitizer Ro-03-8799 to normal and tumour-bearing mice [15].

Anatomical context of NSC318502


Associations of NSC318502 with other chemical compounds


Analytical, diagnostic and therapeutic context of NSC318502


  1. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Arcasoy, M.O., Amin, K., Chou, S.C., Haroon, Z.A., Varia, M., Raleigh, J.A. Clin. Cancer Res. (2005) [Pubmed]
  2. Hypoxia and differentiation in squamous cell carcinomas of the uterine cervix: pimonidazole and involucrin. Azuma, Y., Chou, S.C., Lininger, R.A., Murphy, B.J., Varia, M.A., Raleigh, J.A. Clin. Cancer Res. (2003) [Pubmed]
  3. A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole). Bleehen, N.M., Newman, H.F., Maughan, T.S., Workman, P. Int. J. Radiat. Oncol. Biol. Phys. (1989) [Pubmed]
  4. Effects of localised tumour hyperthermia on pimonidazole (Ro 03-8799) pharmacokinetics in mice. Walton, M.I., Bleehen, N.M., Workman, P. Br. J. Cancer (1989) [Pubmed]
  5. Ro 03-8799: preferential relative uptake in human tumor xenografts compared to a murine tumor: comparison with SR-2508. Lespinasse, F., Thomas, C., Bonnay, M., Malaise, E.P., Guichard, M. Int. J. Radiat. Oncol. Biol. Phys. (1989) [Pubmed]
  6. Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. Dearling, J.L., Flynn, A.A., Sutcliffe-Goulden, J., Petrie, I.A., Boden, R., Green, A.J., Boxer, G.M., Begent, R.H., Pedley, R.B. J. Nucl. Med. (2004) [Pubmed]
  7. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Raleigh, J.A., Chou, S.C., Bono, E.L., Thrall, D.E., Varia, M.A. Int. J. Radiat. Oncol. Biol. Phys. (2001) [Pubmed]
  8. Relationship of hypoxia to metallothionein expression in murine tumors. Raleigh, J.A., Chou, S.C., Tables, L., Suchindran, S., Varia, M.A., Horsman, M.R. Int. J. Radiat. Oncol. Biol. Phys. (1998) [Pubmed]
  9. Radiosensitization by the combination of etanidazole (SR-2508) and pimonidazole (Ro 03-8799) in human tumor xenografts. Taghian, A., Lespinasse, F., Guichard, M.E. Int. J. Radiat. Oncol. Biol. Phys. (1991) [Pubmed]
  10. The effects of whole body hyperthermia on the pharmacokinetics and toxicity of the basic 2-nitroimidazole radiosensitizer Ro 03-8799 in mice. Walton, M.I., Bleehen, N.M., Workman, P. Br. J. Cancer (1987) [Pubmed]
  11. Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia. Danielsson, B.R., Sköld, A.C., Johansson, A., Dillner, B., Blomgren, B. Toxicol. Appl. Pharmacol. (2003) [Pubmed]
  12. Cytocidal effects of misonidazole, Ro 03-8799, and RSU-1164 on euoxic and hypoxic BP-8 murine sarcoma cells at normal and elevated temperatures. Hofer, K.G., Lakkis, M., Hofer, M.G. Cancer (1989) [Pubmed]
  13. Pharmacokinetics of Ro 03-8799 in mice bearing melanosarcoma: comparison with tumors without melanin. Laurent, F., Canal, P., Soula, G. Int. J. Radiat. Oncol. Biol. Phys. (1989) [Pubmed]
  14. The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study. Saunders, M.I., Dische, S., Fermont, D., Bishop, A., Lenox-Smith, I., Allen, J.G., Malcolm, S.L. Br. J. Cancer (1982) [Pubmed]
  15. Effects on intermediary metabolism in mouse tissues by Ro-03-8799. Tamulevicius, P., Luscher, G., Streffer, C. Br. J. Cancer (1987) [Pubmed]
  16. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics. Newman, H.F., Bleehen, N.M., Workman, P. Int. J. Radiat. Oncol. Biol. Phys. (1986) [Pubmed]
  17. Morphological changes in rat hepatocytes in primary culture induced by Misonidazole, desmethylmisonidazole and Ro 03-8799. Smith, R.A. Virchows Arch., B, Cell Pathol. (1984) [Pubmed]
  18. Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole). Newman, H.F., Bleehen, N.M., Ward, R., Workman, P. Int. J. Radiat. Oncol. Biol. Phys. (1988) [Pubmed]
  19. In vitro assessment of the oncogenic potential of nitroimidazole radiosensitizers. Hei, T.K., Geard, C.R., Osmak, R.S., Hall, E.J. Int. J. Radiat. Oncol. Biol. Phys. (1985) [Pubmed]
  20. A comparative study of Ro 03-8799: racemic mixture and enantiomers. Newman, H.F., Dunphy, E.P., Bleehen, N.M., Dische, S., Saunders, M.I., Des Rochers, C., Workman, P., Lenox-Smith, I., Smithen, C.E. The British journal of radiology. (1986) [Pubmed]
  21. Radiotherapy using the hypoxic cell sensitizer Ro 03-8799 in malignant melanoma. Dische, S. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. (1987) [Pubmed]
  22. The pharmacokinetics of a new radiosensitiser, Ro 03-8799 in humans. Allen, J.G., Dische, S., Lenox-Smith, I., Malcolm, S.L., Saunders, M.I. Eur. J. Clin. Pharmacol. (1984) [Pubmed]
  23. Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. Bernsen, H.J., Rijken, P.F., Peters, J.P., Bakker, J.H., Boerman, R.H., Wesseling, P., van der Kogel, A.J. J. Neurooncol. (1999) [Pubmed]
WikiGenes - Universities